A narrative review of the evolving role of immunotherapy in the management of esophageal and gastric cancer

Madan, Ankit; Uronis, Hope E.; Strickler, John H.

doi:10.21037/jgo-22-55

Cited by 5 publications

(5 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSI-H/dMMR is detected in up to 8% of patients with mGC. Early treatment with checkpoint inhibitors may be particularly beneficial in this patient population but data are limited by the relative rarity of MSI-H/dMMR disease ( 30 , 51 ).…”

Section: Tumor Markersmentioning

confidence: 99%

The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion

Cascinu

Bartolomeo²,

Beretta³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Gastric cancer (GC) is recognized as one of the most common deadly malignancies worldwide and about 40–50% of patients present at diagnosis with an unresectable disease due to a locally advanced or already metastatic condition. Recently, therapeutic options for management of metastatic GC (mGC) have been approved allowing a potential improvement of patient cancer treatment response and also an establishment of a continuum of care for this aggressive disease. This report is the result of a literature review by an expert panel. The aim of this document is to provide evidence, wherever it is lacking, to provide expert opinion directed at strategic management of mGC, and in particular aspect at practical management where appropriate guidelines are not available. Treatment landscape with new therapeutic strategies for third line and beyond, role of imaging, prognostic factors, symptoms, and markers as well as the importance of multidisciplinary approach particularly the nutritional aspects are discussed.

show abstract

Section: Tumor Markersmentioning

confidence: 99%

The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion

Cascinu

Bartolomeo²,

Beretta³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Triple-negative breast cancer (TNBC) is a serious form of breast cancer affecting women and has a poor prognosis owing to its malignant behaviors, including metastasis and early tumor recurrence. , TNBC treatment still presents major clinical challenges due to the paucity of effective therapeutic molecular targets . Cancer immunotherapy prolongs the survival rate of patients with solid tumor and represents a promising therapeutic strategy for cancer treatment. − However, only about 15% of TNBC patients could benefit from immunotherapy due to TNBC tumors are typical “cold” tumors with a complicated tumor immunosuppressive microenvironment (TIME) and low immune responses. , Therefore, remodeling the TIME has been regarded as a crucial target for research on combinatorial immunotherapeutic strategies with obvious advantages …”

Section: Introductionmentioning

confidence: 99%

Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy

Bai,

Liu,

You

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer for which effective therapies are lacking. Targeted remodeling of the immunosuppressive tumor microenvironment (TME) and activation of the body’s immune system to fight tumors with well-designed nanoparticles have emerged as pivotal breakthroughs in tumor treatment. To simultaneously remodel the immunosuppressive TME and trigger immune responses, we designed two potential therapeutic nanodelivery systems to inhibit TNBC. First, the bromodomain-containing protein 4 (BRD4) inhibitor JQ1 and the cyclooxygenase-2 (COX-2) inhibitor celecoxib (CXB) were coloaded into chondroitin sulfate (CS) to obtain CS@JQ1/CXB nanoparticles (NPs). Then, the biomimetic nanosystem MM@P3 was prepared by coating branched polymer poly(β-amino ester) self-assembled NPs with melittin embedded macrophage membranes (MM). Both in vitro and in vivo, the CS@JQ1/CXB and MM@P3 NPs showed excellent immune activation efficiencies. Combination treatment exhibited synergistic cytotoxicity, antimigration ability, and apoptosis-inducing and immune activation effects on TNBC cells and effectively suppressed tumor growth and metastasis in TNBC tumor-bearing mice by activating the tumor immune response and inhibiting angiogenesis. In summary, this study offers a novel combinatorial immunotherapeutic strategy for the clinical TNBC treatment.

show abstract

“…Immunotherapy has recently become the focus of considerable research attention, building a good foundation for the development of GI cancer treatments ( 18 , 19 ). Nevertheless, the efficacy of immune checkpoint blockade therapy is greatly limited by the low immunogenicity and immunosuppressive microenvironment of GI cancer.…”

Section: Introductionmentioning

confidence: 99%

PD-1 inhibition combined with intensity-modulated radiotherapy, to better serve patients with retroperitoneal lymph node metastases from gastrointestinal cancer

Lu,

Fang,

Tao

et al. 2024

J Gastrointest Oncol

View full text Add to dashboard Cite

Background Gastrointestinal (GI) cancer is the most frequent kind of cancer to involve the retroperitoneal lymph nodes (RPLNs). Radiotherapy (RT) is common treatment of RPLN metastases in patients with GI cancer, while RT is local. Meanwhile, most patients have extra-retroperitoneal metastases. Immunotherapy plus RT have showed effective in advanced non-small cell lung cancer. However, whether the combination therapy is effective on GI cancer with RPLN metastases. In our study, we would estimate the effect of programmed death-1 (PD-1) inhibition in association with intensity modulated radiation therapy (IMRT). Methods Metastatic GI cancer patients with RPLN who were treated at a single institution were retrospectively evaluated from October 2016 to April 2023, who all had measurable lesion and received any therapy of PD-1 inhibitors alone, IMRT alone or PD-1 inhibitors plus IMRT. The follow-ups were assessed by abdominal computed tomography (CT) every 2 or 3 months to progression, dose-limiting toxicity or death. Results Among the 98 patients, 46 were treated by PD-1 inhibitors combined with IMRT, 26 were by PD-1 inhibitors only and 26 were by IMRT only. Of those, the median age 62 years (range, 25–84 years). Median progression-free survival (PFS) was 7.5 months and median overall survival (OS) was 10.8 months across the 3 therapy groups. Univariate analysis (UVA) indicated that therapy method (P=0.032) and tumor response (P=0.035) were significantly related to PFS. In the PD-1 inhibitors plus IMRT group, 1 patient (2.2%) achieved complete response (CR), 30 (65.2%) had partial remission, and 14 (30.4%) had stable disease. There was no case with CR by IMRT or PD-1 inhibitors alone. Objective response rate (67.4%) and disease control rate (97.8%) were higher in the PD-1 inhibitors combined with IMRT group. In the PD-1 inhibitors plus IMRT and PD-1 inhibitors alone groups, hepatitis B virus (HBV)-positive patients had better OS (P=0.041) on UVA. Meanwhile, in the PD-1 inhibitors plus IMRT group, we observed superior PFS (P=0.041) and OS (P=0.049) in HBV-positive patients on UVA. Conclusions PD-1 inhibitors plus IMRT may be a better method for advanced GI cancer patients with RPLN metastases. HBV-positive patients can benefit from either PD-1 inhibitors alone or in combination with IMRT.

show abstract

A narrative review of the evolving role of immunotherapy in the management of esophageal and gastric cancer

Cited by 5 publications

References 64 publications

The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion

The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion

Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy

PD-1 inhibition combined with intensity-modulated radiotherapy, to better serve patients with retroperitoneal lymph node metastases from gastrointestinal cancer

Contact Info

Product

Resources

About